Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally approved for type 2 diabetes that’s now used off-label and under brand names Wegovy® and Ozempic® for weight management. It mimics the naturally occurring hormone GLP-1 to help regulate blood sugar and appetite.  

Semaglutide slows gastric emptying, reduces appetite signals in the brain, and enhances insulin secretion when blood sugar is high. This combination leads to reduced calorie intake, sustained satiety between meals, and improved glycemic control. 

– Ozempic® (0.5 mg, 1 mg, 2 mg weekly injection) for type 2 diabetes  
– Wegovy® (2.4 mg weekly injection) specifically for chronic weight management  
– Rybelsus® (7 mg, 14 mg daily oral tablet) for type 2 diabetes 

Adults with a body mass index (BMI) ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity (e.g., hypertension, sleep apnea). Candidates should be willing to adopt lifestyle changes and commit to weekly injections or daily tablets under medical supervision. 

Semaglutide for weight loss is given as a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm.

Weight-loss protocols start at 0.25 mg weekly for the first month, escalating every four weeks to 0.5 mg, 1 mg, and up to 2.4 mg (for Wegovy®). This gradual titration minimizes gastrointestinal side effects. 

Many patients notice reduced appetite and slight weight loss within 4–6 weeks. Maximal weight-loss effects typically emerge after 16–20 weeks at the full maintenance dose, in combination with diet and exercise. 

Gastrointestinal symptoms are most common:  
– Nausea, vomiting, diarrhea or constipation  
– Early satiety or bloating  
– Occasional injection-site redness or discomfort  

These often subside after 2–4 weeks of dose escalation.

Semaglutide carries a warning for possible thyroid C-cell tumors (medullary thyroid carcinoma) and pancreatitis. It’s contraindicated in patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or severe gastrointestinal disease.  

Keep injectable pens refrigerated (36–46 °F) until first use; once in use, it may be stored at room temperature (59–86 °F) for up to 56 days. Protect from light and discard any pen 6 weeks after first use. Rybelsus® tablets should be kept in their original blister pack at room temperature, away from moisture. 

A typical semaglutide prescription (Ozempic®, Wegovy® or Rybelsus®) costs between $800 and $1,200 per month if you’re paying cash, depending on dose and brand.

Yes. Send us a message to get your personalized coupon and receive a huge discount from us!

Tirzepatide (Mounjaro®, Zepbound™) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By activating both receptors, it enhances insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety more robustly than GLP-1 agonists alone. 

Think of Semaglutide as a gentle helper that tells your brain, “Hey, you’re full,” so you naturally eat less. Most people lose about 10–15% of their starting weight, see steadier blood sugars, and even get the option of a daily pill or a once-weekly shot.

Tirzepatide does the same job but on two fronts—so it often makes you feel even fuller, curbs cravings more strongly, and drives bigger results (around 20% weight loss on average). The trade-off is it’s only available as a once-weekly injection, but you’ll notice more appetite control and lean-mass preservation compared to a single-pathway drug.

– Mounjaro® (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly pen) for type 2 diabetes  
– Zepbound™ (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly pen or vial) for chronic weight management 

Adults with type 2 diabetes needing improved glycemic control or adults with a BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with comorbidities) seeking weight reduction. Ideal candidates commit to once-weekly injections, lifestyle changes, and regular monitoring. 

Tirzepatide is given once weekly via a subcutaneous injection in the abdomen, thigh, or upper arm. Prefilled auto-injector pens or single-dose vials with insulin-syringes are both options.  

Start at 2.5 mg weekly for four weeks, then increase by 2.5 mg every four weeks up to a maximum of 15 mg weekly. This slow uptitration reduces gastrointestinal intolerance and maximizes tolerability. 

In clinical trials, patients on 10 mg and 15 mg doses lost an average of 20–23% of their body weight over 72 weeks. Even lower doses (5 mg, 7.5 mg) deliver 10–15% reductions, outpacing many other injectable therapies. 

The most frequent adverse effects are gastrointestinal:  
– Nausea, vomiting, diarrhea, constipation  
– Decreased appetite or dyspepsia  
– Mild injection-site reactions  

These generally resolve within 4–8 weeks of initiation or dose increases. 

Tirzepatide may increase risk of thyroid C-cell tumors and pancreatitis. It’s contraindicated in patients with a history of medullary thyroid carcinoma, MEN 2, or severe gastrointestinal disease. Caution in patients with a history of pancreatitis or gallbladder disease. 

Yes. If discontinuation is necessary, you may stop without tapering, but monitor blood glucose closely. In combination with insulin secretagogues, you might need to adjust or reduce those doses to avoid hypoglycemia. 

Refrigerate unused pens or vials at 36–46 °F. Once in use, store at room temperature (59–86 °F) and discard after 21 days. Protect from light and always check the expiration date before use.